|
|
|
|
| LEADER |
00000cam a2200000Mi 4500 |
| 001 |
SCIDIR_ocn967683802 |
| 003 |
OCoLC |
| 005 |
20231120112204.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
170104s2017 enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d N$T
|d IDEBK
|d EBLCP
|d OPELS
|d N$T
|d OCLCF
|d OCLCQ
|d UPM
|d OCLCQ
|d COO
|d OCLCO
|d MERER
|d OCLCQ
|d OTZ
|d OCLCQ
|d OCLCA
|d D6H
|d DKU
|d U3W
|d CNCGM
|d Z5A
|d CASUM
|d UAB
|d LVT
|d AU@
|d OCLCO
|d OCLCQ
|d OCLCO
|d S2H
|d OCLCO
|d OCLCA
|d OCLCO
|d INARC
|
| 019 |
|
|
|a 967655869
|a 967769873
|a 970384668
|a 973002983
|
| 020 |
|
|
|a 9780128037126
|q (electronic bk.)
|
| 020 |
|
|
|a 0128037121
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128036907
|
| 020 |
|
|
|z 0128036907
|
| 035 |
|
|
|a (OCoLC)967683802
|z (OCoLC)967655869
|z (OCoLC)967769873
|z (OCoLC)970384668
|z (OCoLC)973002983
|
| 050 |
|
4 |
|a RC523
|
| 060 |
|
4 |
|a 2017 D-046
|
| 060 |
|
4 |
|a WT 155
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.8/311
|2 23
|
| 245 |
0 |
0 |
|a Neuroprotection in Alzheimer's disease /
|c edited by Illana Gozes.
|
| 260 |
|
|
|a London, United Kingdom :
|b Academic Press,
|c 2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Cover; Title page; Copyright Page; Dedication; Contents; List of Contributors; Acknowledgments; Chapter 1 -- Introduction; Chapter 2 -- Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer's Disease; Introduction; Global health care burden of Alzheimer's disease: epidemiological data; Etiopathogenesis of Alzheimer's disease: what do we know?; Therapeutic approaches to Alzheimer's disease: the promises, the failures, and the future; Neural regeneration-based therapeutic approach for AD: the rationale, the promise, and the progress.
|
| 505 |
8 |
|
|a Neurotrophic factor small-molecule mimetics for Alzheimer's diseaseEnhancement of neurogenesis and memory by CNTF small-molecule mimetics; CNTF-derived neurogenic/neurotrophic compound, P021, can exert a disease-modifying effect in a transgenic mouse model of AD; Summary and conclusions; References; Chapter 3 -- Animal Models of Alzheimer's Disease; Introduction; The genetics of Alzheimer's disease; Transgenic models of amyloidogenesis; Amyloid precursor protein transgenic mice; PDAPP transgenic mice; Histopathology; Behavior; Synaptic Plasticity; Tg2576 transgenic mice; Histopathology.
|
| 505 |
8 |
|
|a BehaviorSynaptic Plasticity; APP23 transgenic mice; Histopathology; Behavior; Synaptic Plasticity; J20 transgenic mice; Histopathology; Behavior; Synaptic Plasticity; APP knock-in transgenic mice; Histopathology; Behavior; Synaptic Plasticity; APP/PS1 transgenic mice; Histopathology; Behavior; Synaptic Plasticity; 5xFAD transgenic mice; Histopathology; Behavior; Synaptic Plasticity; Tau transgenic mice; Tau tg mice under tau promoter; Histopathology; Behavior; Synaptic Plasticity; 3xTg transgenic mice; Histopathology; Behavior; Synaptic Plasticity; Animal models for late onset of AD.
|
| 505 |
8 |
|
|a ApoE Transgenic MiceApoE Knock-Out Transgenic Mice; ApoE2/ApoE3/ApoE4 Knock-In Transgenic Mice; GFAP-ApoE4/ApoE Knock-Out Transgenic Mice; ApoE/APP Transgenic Mice; Nonmouse models; Studies in nematodes; Studies in fruit flies; Nontransgenic models for the study of AD; How to choose the right model?; Summary; Acknowledgment; References; Chapter 4 -- Mechanisms of Neuronal Microtubule Loss in Alzheimer's Disease; Introduction; Studies on Alzheimer's brain and animal models; Are microtubules destabilized in the Alzheimer's brain?; Mechanisms of microtubule loss in the Alzheimer's brain.
|
| 505 |
8 |
|
|a Strategies for treatmentAcknowledgments; References; Chapter 5 -- Tau-Centric Therapies for Treating Alzheimer's Disease; Introduction; Six Tau Isoforms-Many Tau Functions; Mechanisms of Tau Toxicity: Phosphorylation, Microtubule Destabilization, and Aggregation; Tau-centric therapeutic strategy 1: targeting tau phosphorylation; Tau Phosphorylation in Physiological and Pathological States; Mechanisms for Stimulating Tau Phosphorylation; Consequences of Phosphorylation; Therapeutic Strategies to Inhibit Tau Phosphorylation; Current State of Affairs.
|
| 650 |
|
0 |
|a Alzheimer's disease.
|
| 650 |
|
0 |
|a Alzheimer's disease
|x Prevention.
|
| 650 |
1 |
2 |
|a Alzheimer Disease
|x prevention & control
|0 (DNLM)D000544Q000517
|
| 650 |
2 |
2 |
|a Neuroprotection
|0 (DNLM)D000066829
|
| 650 |
|
2 |
|a Alzheimer Disease
|0 (DNLM)D000544
|
| 650 |
|
6 |
|a Maladie d'Alzheimer.
|0 (CaQQLa)201-0114128
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Alzheimer's disease.
|2 fast
|0 (OCoLC)fst00806532
|
| 650 |
|
7 |
|a Alzheimer's disease
|x Prevention.
|2 fast
|0 (OCoLC)fst00806584
|
| 655 |
|
0 |
|a Computer network resources.
|
| 655 |
|
4 |
|a Fulltext.
|
| 655 |
|
4 |
|a Internet Resources.
|
| 700 |
1 |
|
|a Gozes, Illana,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Neuprotection in Alzheimer's disease.
|d London, United Kingdom : Academic Press, 2017
|z 0128036907
|z 9780128036907
|w (OCoLC)959871992
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128036907
|z Texto completo
|
